U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%

U.S. stocks showed mixed results with gains in some sectors and losses in others, influenced by notable performers, market breadth, and commodities trading.

Vertex shares downgraded at Oppenheimer amid LSR trial uncertainties

Oppenheimer downgraded Vertex Pharmaceuticals after suzetrigine failed to significantly outperform placebo in Phase 2 trials for painful lumbosacral radiculopathy, affecting its stock rating and price target.

Vertex shares tumble following Phase 2 pain study results

Vertex Pharmaceuticals shares fell 12% after Phase 2 studies of suzetrigine showed similar results to placebo, raising concerns over the drug's efficacy despite meeting its primary endpoint.

Investing.com poll: Will a Santa Claus rally push stocks higher into year-end?

Citi initiates coverage on 5 new biotech stocks

Citigroup added five biotech stocks, giving Buy ratings to Gilead and Vertex, while Amgen, Biogen, and Regeneron received Neutral ratings due to various market challenges.

RBC's top 10 questions and answers on biotech stocks

RBC Capital Markets reveals top 10 investor questions on biotech sector, focusing on FDA impact, major companies' strategies, upcoming trial data, and market sentiment.

Earnings call: Vertex Pharmaceuticals Q3 2024 revenue climbs 12%

Vertex earnings beat by $0.30, revenue topped estimates

Vertex reported strong Q3 earnings, with EPS of $4.38 and revenue of $2.77B, exceeding estimates and projecting positive FY 2024 revenue guidance.

Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength

Vertex Pharmaceuticals raised its revenue forecast after strong demand for cystic fibrosis treatments, projecting 2024 revenue between $10.8 billion and $10.9 billion.

Stock market today: S&P 500 closes lower ahead of presidential election

The S&P 500 declined as investors were cautious before the presidential election and the Fed's expected rate cut, with concerns about inflation and tech sector impacts.